Susie Lu has over 30 years of experience in leading and expanding healthcare ancillary and ambulatory services domestically and internationally. She has held key executive leadership positions, with operational, strategic, and financial responsibilities at organizations such as Columbia HCA, Stanford Hospital and Clinics, Lucile Packard Children’s Hospital, UCSF Medical Center, and UCLA Healthcare System. Under her leadership, she has developed, implemented, and expanded innovative technology through major outreach services.
Dr. Douglas Harrington has over 25 years of experience in the research, development, and translation into clinical use of innovative healthcare technology and services. Dr. Harrington was a resident member of one of the first heart transplant teams led by Dr. Jack Copeland from Stanford University. He co-founded one of the first clinical molecular biology laboratories in the U.S. with the Nebraska Lymphoma Study Group headed by Dr. Jim Armitage.
Dr. Harrington has developed multiple patents including detection of residual cancer cells, catalytic heavy metal extraction, and a patent pending for diagnosis and classification of cardiac disease. Dr. Harrington has taken over 200 academic discoveries into clinical use, founded a number of public and private biotechnology companies, and his PULS (Protein Unstable Lesion Signature) Cardiac Test was the recipient of the 2016 ABL Grand Prize Award for Innovation in Healthcare. Dr. Harrington focuses on disease prevention and is Medical Director for the Tshimakain (T-creek) First Nation Research and Diagnostic laboratory in Spokane (the first Native American owned Cardiac research facility),a published author of numerous peer-reviewed papers, and a sought-after speaker in the area of preventive medicine and technology development. Dr.Harrington received his BA in molecular biology, and MD from the University of Colorado Health Sciences Center, and is the Chairman & Laboratory Director of Predictive Health Diagnostics.
Kevin McFarlane is the founder of Venerable Holdings whose mission is to partner with emerging companies with the ability to significantly disrupt their chosen market segment. Venerable Holdings seeks to identify global megatrends and the technology solutions to solve critical problems specifically focused on maximizing societal impact. In addition to the infusion of capital, the firm also provides corporate strategy business development, corporate finance and M&A expertise.
Mr. McFarlane has over 25 years working with growing enterprises. Most recently, he was a partner at Deloitte with specific responsibilities as one of the national leaders for their middle market practice, Deloitte Growth Enterprise Services. In addition, he was a leader of the firm’s Corporate Finance practice. Prior to joining Deloitte, Mr. McFarlane was with Goldman, Sachs & Co. serving as a senior banker in their Corporate Finance, Mergers and Strategic Advisory groups covering the Western US.
Mr. McFarlane received his AB from Harvard College ad his MBA from the Stanford Graduate School of Business.
Stavros Demos is a Senior Scientist and the Group Leader of the Optical Materials Technologies Group at University of Rochester’s Laboratory for Laser Energetics (LLE). He joined LLE in 2016 after almost 20 years as a Scientist at Lawrence Livermore National Laboratory. He received his B.S. in Physics from the University of Ioannina, Greece and his Ph.D. in Physics in 1993 from the City University of New York His research is focused in the areas of defect characterization in optical materials for high-power/peak-intensity laser systems and the dynamics of material response following localized energy deposition. His current research interests also extend to in the fields of additive manufacturing and biomedical optics toward developing instrumentation for rapid and in-vivo detection of disease and monitoring of therapeutic intervention. Stavros is a Fellow of the American Physical Society and of the Optical Society of America.